JP7668227B2 - 血漿カリクレイン阻害剤および眼障害におけるその使用方法 - Google Patents

血漿カリクレイン阻害剤および眼障害におけるその使用方法 Download PDF

Info

Publication number
JP7668227B2
JP7668227B2 JP2021559442A JP2021559442A JP7668227B2 JP 7668227 B2 JP7668227 B2 JP 7668227B2 JP 2021559442 A JP2021559442 A JP 2021559442A JP 2021559442 A JP2021559442 A JP 2021559442A JP 7668227 B2 JP7668227 B2 JP 7668227B2
Authority
JP
Japan
Prior art keywords
months
compound
pharmaceutical composition
administration
scs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021559442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526999A5 (https=
JP2022526999A (ja
Inventor
バブー，ヤーラガッダ
カンサラ，バイラル
マケルヘニー，リック
Original Assignee
バイオクライスト ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72750647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7668227(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by バイオクライスト ファーマシューティカルズ， インコーポレイテッド filed Critical バイオクライスト ファーマシューティカルズ， インコーポレイテッド
Publication of JP2022526999A publication Critical patent/JP2022526999A/ja
Publication of JP2022526999A5 publication Critical patent/JP2022526999A5/ja
Priority to JP2025065469A priority Critical patent/JP2025108562A/ja
Application granted granted Critical
Publication of JP7668227B2 publication Critical patent/JP7668227B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021559442A 2019-04-08 2020-04-08 血漿カリクレイン阻害剤および眼障害におけるその使用方法 Active JP7668227B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025065469A JP2025108562A (ja) 2019-04-08 2025-04-11 血漿カリクレイン阻害剤および眼障害におけるその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962830802P 2019-04-08 2019-04-08
US62/830,802 2019-04-08
PCT/US2020/027287 WO2020210368A1 (en) 2019-04-08 2020-04-08 Plasma kallikrein inhibitors and methods of use thereof in ocular disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025065469A Division JP2025108562A (ja) 2019-04-08 2025-04-11 血漿カリクレイン阻害剤および眼障害におけるその使用方法

Publications (3)

Publication Number Publication Date
JP2022526999A JP2022526999A (ja) 2022-05-27
JP2022526999A5 JP2022526999A5 (https=) 2023-04-12
JP7668227B2 true JP7668227B2 (ja) 2025-04-24

Family

ID=72750647

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559442A Active JP7668227B2 (ja) 2019-04-08 2020-04-08 血漿カリクレイン阻害剤および眼障害におけるその使用方法
JP2025065469A Pending JP2025108562A (ja) 2019-04-08 2025-04-11 血漿カリクレイン阻害剤および眼障害におけるその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025065469A Pending JP2025108562A (ja) 2019-04-08 2025-04-11 血漿カリクレイン阻害剤および眼障害におけるその使用方法

Country Status (7)

Country Link
US (1) US12589093B2 (https=)
EP (1) EP3953395B1 (https=)
JP (2) JP7668227B2 (https=)
AU (1) AU2020273154A1 (https=)
CA (1) CA3136326A1 (https=)
IL (1) IL287066B1 (https=)
WO (1) WO2020210368A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017525718A (ja) 2014-08-22 2017-09-07 バイオクライスト ファーマシューティカルズ， インコーポレイテッド アミジン誘導体組成物及びそれらの使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104541A2 (en) * 2006-03-16 2007-09-20 Dyax Corp. Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
CA2933900A1 (en) * 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents
KR102736869B1 (ko) * 2014-03-07 2024-12-02 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
US10428158B2 (en) * 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
CA3041058A1 (en) 2016-10-31 2018-05-03 Biocryst Pharmaceuticals, Inc. Carbamimidoylphenylcarbamoyl derivatives and pharmaceutical compositions thereof useful as kallikrein inhibithors
AU2018226872A1 (en) * 2017-03-03 2019-09-05 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
JP2020528082A (ja) 2017-07-17 2020-09-17 ロイズマン，キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017525718A (ja) 2014-08-22 2017-09-07 バイオクライスト ファーマシューティカルズ， インコーポレイテッド アミジン誘導体組成物及びそれらの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG J; KRISHNAN R; ARNOLD C S; ET AL，DISCOVERY OF HIGHLY POTENT SMALL MOLECULE KALLIKREIN INHIBITORS，MEDICINAL CHEMISTRY，NL，BENTHAM SCIENCE PUBLISHERS LTD，2006年，VOL:2，PAGE(S):545 - 553，https://www.ncbi.nlm.nih.gov/pubmed/17105435

Also Published As

Publication number Publication date
JP2025108562A (ja) 2025-07-23
US12589093B2 (en) 2026-03-31
US20220160694A1 (en) 2022-05-26
AU2020273154A1 (en) 2021-12-02
EP3953395A4 (en) 2023-01-18
EP3953395A1 (en) 2022-02-16
CA3136326A1 (en) 2020-10-15
JP2022526999A (ja) 2022-05-27
IL287066B1 (en) 2026-01-01
EP3953395B1 (en) 2026-05-06
IL287066A (en) 2021-12-01
WO2020210368A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
AU2004260645B2 (en) Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle
Nagai et al. A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
US20100278896A1 (en) Solid compositions
NZ725574A (en) Compounds for treating ophthalmic diseases and disorders
KR20180004164A (ko) 글루코코르티코스테로이드의 나노미립자를 함유하는 수성 현탁액제
US20250213541A1 (en) Suspension compositions of multi-target inhibitors
JP7470791B2 (ja) 眼疾患の予防または治療用点眼組成物
JP7668227B2 (ja) 血漿カリクレイン阻害剤および眼障害におけるその使用方法
CA3201534A1 (en) Compounds for treating eye diseases and disorders
EP1867334A1 (en) Method of relieving or avoiding side effect of steroid compound
CA3177104A1 (en) N-acetylserotonin derivatives as trkb activators and uses thereof
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
EP3851097A1 (en) Controlled release formulations
JP2006257080A (ja) ステロイド化合物の副作用軽減または回避方法
Rahic et al. Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions. Pharmaceutics 2021, 13, 28
CN114028421A (zh) 一种使用泊洛沙姆用于治疗眼部疾病的方法
TW202038928A (zh) 多目標抑製劑的懸浮液組合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250414

R150 Certificate of patent or registration of utility model

Ref document number: 7668227

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157